In Vivo Screening Data Summary

NCI In Vivo Screening Data

Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice

NSC 362856
CAS 85622-93-1
Temozolomide; Methazolastone; Temodar

Chemical Data
Schedule (route) Endpoint Vehicle Dose Treated/Control (%) Observations
Q04DX003 (ip) mean tumor weight change saline 150.0 mg/kg/injection 24.0 Antitumor endpoint evaluated on day 11; 06/06 animals surviving on day 11
Q04DX003 (ip) mean tumor weight change saline 300.0 mg/kg/injection -68.0 Antitumor endpoint evaluated on day 11; 05/06 animals surviving on day 11
Q04DX003 (ip) mean tumor weight change saline 600.0 mg/kg/injection 0.0 Antitumor endpoint evaluated on day 11; 00/06 animals surviving on day 11
Q04DX003 (ip) mean tumor weight change saline 1200.0 mg/kg/injection 0.0 Antitumor endpoint evaluated on day 11; 00/06 animals surviving on day 11
Q04DX003 (ip) mean tumor weight change suspension in saline 75.0 mg/kg/injection 68.0 Antitumor endpoint evaluated on day 11; 06/06 animals surviving on day 11
Q04DX003 (ip) mean tumor weight change suspension in saline 150.0 mg/kg/injection 15.0 Antitumor endpoint evaluated on day 11; 06/06 animals surviving on day 11
Q04DX003 (ip) mean tumor weight change suspension in saline 300.0 mg/kg/injection -100.0 Antitumor endpoint evaluated on day 11; 05/06 animals surviving on day 11
Q04DX003 (ip) mean tumor weight change suspension in saline 600.0 mg/kg/injection 0.0 Antitumor endpoint evaluated on day 11; 00/06 animals surviving on day 11